Clinical translation of carfilzomib trial data for MM treatment

Clinical translation of carfilzomib trial data for MM treatment

VJHemOnc

2 years
114 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The proteasome inhibitor carfilzomib has been investigated for the treatment of relapsed/refractory multiple myeloma (MM) in two Phase III clinical trials, ASPIRE (NCT01080391) and ENDEAVOUR (NCT01080391), with promising results. In this interview, Greg Friberg, MD, of Amgen Inc., Thousand Oaks, CA, discuses subanalyses of the robustness of the study data. Dr Friberg highlights how this data will help clinicians to determine the best treatment combinations for their patients. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Up Next Autoplay